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Acute Graft versus Host Disease (aGvHD) grades 2–4 occurs in 15–60% of pediatric patients undergoing allogeneic haematopoietic
stem-cell transplantation (allo-HSCT). The collateral damage to normal tissue by conditioning regimens administered prior to allo-
HSCT serve as an initial trigger for aGvHD. DNA-repair mechanisms may play an important role in mitigating this initial damage, and
so the variants in corresponding DNA-repair protein-coding genes via affecting their quantity and/or function. We explored 51
variants within 17 DNA-repair genes for their association with aGvHD grades 2–4 in 60 pediatric patients. The cumulative incidence
of aGvHD 2–4 was 12% (n= 7) in the exploratory cohort. MGMT rs10764881 (G>A) and EXO rs9350 (c.2270C>T) variants were
associated with aGvHD 2–4 [Odds ratios= 14.8 (0 events out of 40 in rs10764881 GG group) and 11.5 (95% CI: 2.3–191.8),
respectively, multiple testing corrected p ≤ 0.001]. Upon evaluation in an extended cohort (n= 182) with an incidence of aGvHD
2–4 of 22% (n= 40), only MGMT rs10764881 (G>A) remained significant (adjusted HR= 2.05 [95% CI: 1.06–3.94]; p= 0.03) in the
presence of other clinical risk factors. Higher MGMT expression was seen in GG carriers for rs10764881 and was associated with
higher IC50 of Busulfan in lymphoblastoid cells. MGMT rs10764881 carrier status could predict aGvHD occurrence in pediatric
patients undergoing allo-HSCT.
The Pharmacogenomics Journal; https://doi.org/10.1038/s41397-021-00251-7
INTRODUCTION
The most frequent immunological complication after allogeneic
haematopoietic stem-cell transplantation (allo-HSCT) is acute Graft
versus Host Disease (aGvHD), occurring in 15–60% of transplants
in children [1]. In patients receiving HSCT from HLA-identical
siblings, the long-term survival rates with aGvHD grades III–IV are
below 30% [2]. aGvHD begins with host normal tissue damage by
the conditioning regimens that causes pro- and anti-inflammatory
cytokine secretion which subsequently activate the host antigen
presenting cells (this being phase 1 of the pathobiology of aGvHD)
[3]. Thus, the intensity or type of conditioning regimen is
determined as one of the donor-independent risk factors for
aGvHD [4, 5].
Busulfan (BU) is frequently used for conditioning children prior
to allo-HSCT [6]. BU is a bifunctional alkylating agent (AG)
commonly administered with other alkylating agents like cyclo-
phosphamide (CY) or the purine analog Fludarabine (FLU) [7]. BU
and other AGs mediate their cytotoxicity by damaging the DNA
through formation of covalent linkages between the alkyl groups,
mainly the N7 position of guanine, while the N3 position of
cytidine and O6 of guanine also serve as nucleophiles [8]. These
covalent modifications lead to inter- or intra-strand DNA crosslink
formation, which affects the genomic integrity and causes
deleterious consequences during DNA replication. That effect is
observed in tumor cells but also in normal cells, the latter being
linked to the treatment-related toxicities (TRTs) such as aGvHD.
Received: 11 November 2020 Revised: 26 February 2021 Accepted: 6 April 2021
1CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
2Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva,
Switzerland. 3Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada. 4Childhood Cancer Research Group, Institute of Social and
Preventive Medicine, University of Bern, Bern, Switzerland. 5Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada. 6Division of
Haematology, Department of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland. 7Paediatric Blood and Marrow Transplantation Program,
University Medical Center Utrecht, Utrecht, The Netherlands. 8Department of Paediatrics, Leiden University Medical Center, Leiden, The Netherlands. 9Department of Hemato-
immunology, Robert-Debre Hospital, Paris-Diderot University, Paris, France. 10Department of Biochemistry, The Children’s Hospital at Westmead, Westmead, NSW, Australia.
11Department of Paediatric Haematology, Oncology and Stem Cell Transplantation, University Hospital of Regensburg, Regensburg, Germany. 12Department of Pediatrics, St.
Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria. 13Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents,
University Hospital, Goethe University Frankfurt, Frankfurt, Germany. 14The Cancer Centre for Children, The Children’s Hospital at Westmead, Westmead, NSW, Australia.
15Department of Paediatrics, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada. 16These authors contributed equally: C. R. S. Uppugunduri, P. Huezo-Diaz
Curtis. ✉email: Marc.Ansari@hcuge.ch
www.nature.com/tpjThe Pharmacogenomics Journal
Hence, variants related to BU metabolism such as GSTA1*B [9] and
GSTM1-null [10] were described as risk factors for aGvHD. Other
genetic polymorphisms within immunological pathways were also
described as risk factors [11], some of them in a pediatric
population [12].
The DNA damage caused by AG is repaired by various DNA-
repair pathways [8, 13] including base excision repair (BER),
mismatch repair (MMR) and homologous recombination or by
nonhomologous end joining. Other mechanisms include
demethylation of guanine residues by O6-methylguanine-DNA
methyltransferase (MGMT) and MMR of small insertions and
modifications by identifying the damaged base with the help of
Mut L homologue-1 protein [14]. Genomic predictors of inter-
individual differences in response to DNA damaging agents have
previously been demonstrated [15]. Studies have implicated the
role of genetic variants and altered expression of genes in the
DNA-repair pathways particularly BER and MMR in determining
treatment outcomes of AGs [16]. However, less is known about
their role in determining clinical outcomes of BU-based condition-
ing in a pediatric allo-HSCT.
We hypothesized that children receiving allo-HSCT with efficient
DNA-repair ability are at reduced risk of developing aGvHD by
diminishing the activation of Phase 1 of the pathophysiology of
aGvHD. As the DNA damage caused by cross-linking agents like
BU is complex and may involve one or more of the above-
mentioned pathways; in this study candidate genes from key
pathways were therefore investigated as possible biomarkers for
aGvHD. Selected variants (list of the candidates selected and
criteria for the selection of variants are provided in the methods
section) among the genes coding for key proteins of
demethylating repair pathways, BER pathway genes or double-
strand break repair pathways were selected for the investigation
[8, 13, 14, 16].
RESULTS
The characteristics of the study subjects in the exploratory cohort
(n= 60) and extended cohort (n= 187) are given in Table 1. The
incidence of aGvHD 2–4 was 12% (n= 7) in the exploratory cohort
and 22% (n= 40) in the extended cohort.
DNA-repair genetic variants and aGvHD
Hardy–Weinberg equilibrium (HWE) p values and minor allele
frequency (MAF) data for each SNP is presented in Table 2. Five
SNPs were found to be non-polymorphic in our sample set
(ALKBH1 rs17825440; BRCA1 rs28897687; FANCD2 rs9845756; NBN
rs1805794; RAD52 rs7310449). Another three SNPs did not pass at
the genotyping stage due to unreliable amplification of product
(APEX1 rs4585; BRCA1 rs28897687; NBN rs1805800). Forty-three
SNPs were carried forward for statistical analyses. Association
analyses between genotype (additive or dominant model) against
aGvHD 2–4 are illustrated in Fig. 1A. EXO rs9350 and MGMT
rs10764881 showed significance (multiple testing p value ≤0.001,
with an odds ratio of 11.5 (95% CI: 2.3–191.8) and 14.8 (0 events
out of 40). From the extended analysis of these SNPs with aGvHD,
only MGMT rs10764881 (p= 0.03) remained significant (Fig. 1B).
Multivariable analysis (Table 3), adjusting for known risk factors,
indicated that MGMT rs10764881 allele A is an independent risk
factor for aGvHD 2–4 (2.05 [95% CI: 1.06–3.94]; p= 0.03). Altogether
with no serotherapy administration (HR 2.11 [95% CI: 1.08–4.14]; p=
0.03), higher 1st day BU AUC (HR 1.08 [95% CI: 1.01–1.15]; p= 0.03)
and HLA mismatch (HR 1.97 [95% CI: 0.90–4.3; p= 0.08) remained
within the model as risk factors. Multinomial regression examining
MGMT rs10764881 with aGvHD severity demonstrated that the risk
tended to be higher with severe grades of aGvHD, when patients
carried the AA or AG genotypes. However statistical significance was
not reached for determining an increased risk between aGvHD 1 vs.
aGvHD 2–4 based on the genotype (p= 0.3, see Supplementary
Table 1). MGMT rs10764881 was not associated with relapse post-
transplant in patients with malignancies (data not shown).
MGMT mRNA expression pre- and post-busulfan exposure
MGMT mRNA expression demonstrated no significant change
from basal levels (data not shown). Nevertheless, MGMT
rs10764881 showed a change in expression levels irrespective of
the BU treatment (p= 0.01 pretreatment and 0.03 posttreatment;
Supplementary Fig. 1).
Cell viability studies on HAP1 MGMT knockout cell lines and
lymphoblastoid cells (LCLs). There was no significant difference
in inhibitory concentration 50 (IC50) value between HAP1 MGMT
knockout cells (mean IC50= 102.21 µM ± 6.4 µM) and HAP1
parental cells after BU exposure (mean IC50= 117.68 µM ± 16.7
µM) (Supplementary Fig. 2). However, we observed significant
differences (p= 0.02) in the BU IC50 values between LCLs carrying
“GG” and “AG, AA “genotypes for rs10764881 (Supplementary
Fig. 3).
Dual luciferase reporter-gene assays. There was no significant
differences observed in expression levels between the short
plasmid construct containing alleles A and C of variant rs1625649
that is in strong LD (r2= 0.85–1.0 in Europeans), with rs10764881,
(p= 0.53) (Fig. 2). However, the longer plasmid construct contain-
ing variant rs10764881 allele G differed significantly from the
plasmid construct containing variant rs10764881 allele A (p=
0.000005) as well as from the shorter fragment without
rs10764881 (p= 0.000001) suggesting the presence of an
enhancer element near to this SNP, which shows increased
dependency with the presence of allele G.
Dexamethasone-mediated activation of hMGMT promoter
Exposing the cells to dexamethasone increased protein expression
of luciferase in all the plasmids compared to their non-treated
plasmid construct (p < 0.0005). The highest response was seen
from the plasmid construct containing variant rs10764881 allele G
compared to the other treated constructs (p < 0.0007) (Fig. 2).
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) results showed that a
shift is established when nuclear protein is added at varying
concentrations to the predicted GRE probe (Supplementary Figs. 4,
5). The intensity of the shift diminished when unlabeled
competitive probes were added at 100 times higher concentra-
tion, indicating that the DNA-protein binding occurs with the
predicted probe region. Furthermore, interaction appears stronger
when allele G is present in the predicted probe.
DISCUSSION
We showed an association of a variant in MGMT (rs10764881, G>A)
with aGvHD 2–4 incidence, even after adjusting for other known
risk factors (serotherapy, BU AUC and HLA incompatibility). A trend
in association of AA and AG genotype carriers at rs10764881 with
severity of aGvHD was also seen (no aGvHD, 35% vs. aGvHD grade
1, 55% vs. aGvHD 2–4, 66%). These observations suggest efficient
DNA damage repair due to increased MGMT expression and activity
in GG carriers. Minor allele (“A”) frequencies of rs10764881 among
different ethnicities are similar (∼25–30%) except for the African
population (<10%) indicating the utility of this genetic marker
among non-African ethnicities (Supplementary Table 2).The only
other clinical association study that has investigated DNA-repair
genes in relation to aGvHD, assessed BER pathway genes and
reported a significant association with a variant in RFC1 (rs6844176)
in a mixed cohort of adult and pediatric populations [16]. This
variant was not significantly associated with aGvHD in our
exploratory cohort. Thus, to the best of knowledge, this is the first


























N % N %
Gender 0.46
Male 28 47 96 53 Not included




53 88 149 82 Rapid and normal metabolizers
Slow metabolizers 7 12 33 18 Slow metabolizers
Diagnosis 1.00**
Acute lymphoid leukemia 2 3 22 12
Acute myeloid leukemia 18 30 49 27
Myelodysplastic syndrome 16 27 32 18
Myeloproliferative
syndrome
1 2 7 4
Total malignancies 37 62 110 60 Total malignancies
Bone marrow failure 0 0 2 1
Hemoglobinopathies 8 13 22 12
Immunodeficiency 8 13 32 18
Metabolic disease 3 5 9 5
Hemophagocytic syndrome 4 6 7 4
Total non-malignancies 23 38 72 40 Total non-malignancies
HLA compatibility 0.77
Mismatch-unrelated donor 22 37 64 35 MMUD
Mismatch-related donor 2 3 8 4 MMRD
Matched unrelated donor 13 22 51 28 MUD
Matched related donor 23 38 59 32 MRD
Stem cell source 0.06
Bone marrow 26 42 74 41 Bone marrow
Cord blood 33 56 81 45 Cord blood
Peripheral blood 1 2 27 15 Peripheral blood
Myeloablative conditioning <0.05***
BU/CY/MEL 0 0 12 7
BU/CY/VP16* 5 11 9 5
Total number of three
alkylating agents
5 11 21 12 Three alkylating agents
BU/FLU/Thio 0 0 7 4
BU/CY 55 89 95 52
BU/FLU/CY 0 0 3 2
BU/MEL 0 0 1 1
BU/FLU/MEL 0 0 21 12
Total number of two
alkylating agents
55 89 127 68 Two alkylating agents
BU/FLU or FLU/BU 0 0 34 20 One alkylating agent
Serotherapy
No 15 23 65 36 0.038 No
ATG 47 71 114 63 Yes
AL 0 0 3 2
GvHD prophylaxis
Missing data 0 0 1 1 NC
Steroids alone 0 0 2 1 Not included
Cyclosporine+ steroids 33 56 48 26
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report that has evaluated candidate DNA-repair gene variants and
their association with aGvHD after allo-HSCT in children. This report
unfolds the role of DNA-repair pathway gene candidate genes as a
biomarker for stratification of patients at a higher risk of developing
aGvHD post HSCT. Oligogenic risk score development may include
DNA-repair gene variants along with other reported genetic risk
factors in immunological mediators for e.g., interleukin 1 [11],
interferon-gamma, interleukin 10, and TGF-β [17] or busulfan
metabolic pathway [9] to evaluate performance for the prediction
of aGvHD risk post HSCT.
Understanding the effect of DNA-repair gene variation on
normal tissues could also be beneficial for assessing the risk of
TRTs [13]. MGMT encodes the DNA-repair protein O6-alkylguanine
DNA alkyl transferase. It has been studied extensively in
association with methylating-agent resistance [18]. Earlier research
has mainly focused on evaluating the inhibition of MGMT to
augment therapy with alkylating agents. However, Phase I trials
showed that inhibitors that inactivate MGMT, improved the
efficacy of BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) on tumor
cells but were associated with more systemic toxicity [19],
indicating MGMT expression is also vital for protecting from DNA
damage in normal cells. BU preferentially induces N7, N3 guanine,
and N3 adenine lesions and MGMT is known to repair lesions of
alkylation reactions at oxygen sites, such as O6 of guanine. No
significant change in the IC50 values of BU in the absence and
presence of MGMT in HAP1 cells, indicating its limited role in
determining the cytotoxicity caused by BU. However, significant
differences in IC50s of BU was observed between LCLs carrying
different genotypes for rs10764881 in MGMT. GG carriers exhibited
higher BU IC50 values compared to AA and AG carriers
(Supplementary Fig. 3). However, this cannot entirely be attributed
to rs10764881 genotypes, as several other gene variants at the
same time were also associated with changes in BU IC50 in the
LCLs. Multiple testing correction was not applied due to the
limited number of the samples (n= 58). However, LCLs serve as a
good model for investigating the association of potential
pharmacogenetic markers. They represent unrelated individuals
with the marker of interest. Thus, irrespective of the causative
effect, MGMT rs10764881 genotypes could identify cells that are
sensitive to BU or resistant to BU defined based on IC50 values.
Interestingly, this SNP is not in linkage disequilibrium (LD) with
any SNP in the SNPs in the MGMT exonic region, however it is in
strong LD with rs1625649 (R2 > 0.85–1.0) in Europeans (except for
Finnish population) and Americans, (specifically Mexican ancestry
and Peruvian in Lima) and South East Asians (only in Punjabi in
Lahore, Pakistan). A better progression free survival was seen in
glioblastoma patients carrying rs1625649 “AA” genotypes which
was in turn associated with lower MGMT expression [20] and was
also shown to reduce the expression of MGMT as a part of
investigated promoter haplotypes [21]. Thus, the observed
decreased MGMT expression in rs10764881 AG, AA carriers can
be partially explained by AA and AC genotypes at rs16265649
locus and as a result of the interaction between these two loci as
demonstrated in the luciferase assays in this report (Fig. 2). The
allele frequencies of rs1625649 are given in Supplementary
Table 2. In addition to BU induced DNA damage, co-
administering agents with BU such as CY and its metabolites also
contribute to the DNA damage and thus play a role in the
occurrence of aGvHD. MGMT was shown to be involved in
repairing damage caused by acrolein, a cyclophosphamide (CY)
metabolite [22]. Thus, the association observed in this study might
be due to an indirect effect through the interaction of BU with
combination chemotherapy. For e.g., depletion of glutathione
(GSH) reserves by BU conjugation may reduce the elimination of
CY’s metabolite acrolein, etoposide’s metabolite quinone or
melphalan in turn increasing tissue damage [23], which MGMT
could repair. Our results demonstrate that higher 1st day BU
exposure increases the risk of aGvHD incidence. Though, direct
proportional relationship between MGMT and GSH is well known
[24], this needs to be further explored the within an HSCT setting
in relation to the conditioning regimen. O6-methyl guanine
adducts in the absence of MGMT activity could generate point
mutations, mismatching base pairs and lead to the formation of
DNA double-strand breaks (DSB) [25]. Thus, the inter-play between
Table 1 continued
Cyclosporine+MTX 27 44 72 40
CSA+MMF 0 0 12 7
Cyclosporine alone 0 0 39 21
Total number of CSA-based
prophylaxis
171 94 Total CSA-based prophylaxis
Tacrolimus 0 0 3 2
Tacrolimus+MTX 0 0 4 2
Tacrolimus+MMF 0 0 1 1
Total number of TAC-based
prophylaxis
8 4 Total TAC-based prophylaxis
Median Range Median Range
Age (years) 6.4 (6.3) 0.1–19.9 5.6 (5.8) 0.0–23.7 >0.05 Not included
cumAUC (mg.H/L) 63.1 (7.9) 40.82–84.82 63.8 (13.3) 28.8–110.52 >0.05 cumAUC (mg.H/L)
BU Day 1 AUC (mg.H/L)a 12.9 (3.9) 7.3–28.8 13.10 (4.3) 5.90–29.30 >0.05 BU day 1 AUC (mg.H/L)
*GSTA1 genotyping was either performed according to the previously described procedures [9] or with sanger sequencing of the promoter region. GSTA1
metabolic status was based on reporter-gene assays and PK data as described in Ansari et al. [9]. *BU/CY/VP16 was included in this group due to its reported
higher toxicity equal to three alkylating agents.
BU Busulfan, CY Cyclophosphamide, MEL Melphalan, VP16 etoposide, ATG anti-thymocyte globulin, AL alemtuzumab, MTX methotrexate, MMUD mismatch-
unrelated donor, MMRD mismatch-related donor, MUD matched unrelated donor, matched related donor matched related donor, NC p value not calculated as
the distribution of several heterogenous prophylactic combinations exists with no patients receiving this combination in one of the cohorts.
**p value for the distribution of malignancies versus non-malignancies.
***p value for the distribution of single versus two versus three alkylating agents’ usage.
aBU 1st Day AUC s were presented irrespective of the dosing schedule used in the patients (either four times daily for all the four doses combined or once daily
for one dose). AUCs are presented to reflect the exposure of BU in each patient which is a derived pharmacokinetic parameter from observed clearance and
administered doses.
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MGMT repair and other DNA-repair pathways in elucidating the
cell death and toxicity of alkylating agents used in HSCT
conditioning also need to be addressed in future.
Genome wide e-QTL analysis, showed difference in mRNA
expression in relation to rs10764881 across diverse human tissues,
where allele G demonstrated higher expression profiles [26]. These
findings were depicted in LCLs mRNA expression experiments in
this report. Our reporter-gene assays indicate that the region
further upstream (−700 to −1873) might contain an enhancer
element dependent on allele G and to a lesser extent on allele A.
MatInspector tool predicted GREs in the human MGMT promoter
(Supplementary Fig. 4). Longer plasmid constructs (1873bp) that
we used in dual luciferase reporter assays were predicted to have
five GRE’s, while two GREs were predicted for the shorter plasmid
constructs (785 bp). One of these GRE lies within the region
encompassing variant rs10764881 and indicates that perhaps this
variant could disrupt binding. There are no other SNPs that fall
near to any GRE in this region except for rs2782888 (non-
polymorphic in Caucasians but has a MAF of 8% in an African
population, Supplementary Fig. 4). Normally, after glucocorticoid
receptor-steroid binding occurs, this complex is transported to the
nucleus where it can act as a transcription factor enhancing MGMT
expression. One could hypothesize that rs10764881 allele A
disrupts this binding and results in less efficient MGMT transcrip-
tion. By treating HEK cells containing the transfected plasmids
with dexamethasone we were able to confirm that the plasmid
containing SNP rs10764881 A allele demonstrated significantly
lower expression levels (p= 0.0007) compared to the rs10764881
G allele construct, in spite of the number of GREs present. Previous
studies confirmed the inducible effects of dexamethasone on
MGMT mRNA and protein levels through glucocorticoid binding
sites [27]. These results were further confirmed by performing an
EMSA (Supplementary Fig. 5). However, in EMSA the protein-DNA
band did not disappear completely when the competitive control
probe was added suggesting that there could be non-specific
binding or other transcription factors that may compete for
this site.
One of the limitations of our study is the size of the exploratory
cohort that was small and therefore lacked the statistical power to
truly reject false negatives. Nevertheless, the significance of MGMT
rs10764881 association in an extended cohort indicates true
nature of this association. In in vitro MGMT knockout studies
neither promoter methylation pattern nor the activity of MGMT in
both parent and knockout HAP1cells was measured, Further,
multiple clones with and without MGMT expression were not
tested that might explain no significant difference in BU IC50
values between cells with and without MGMT. Super shift assays
with GRE specific antibodies was also not incorporated in EMSA
experiments. The incidences of aGvHD between exploratory and
extended cohort were also different, however, the observed
association remained significant in the extended cohort. The
difference in the observed aGvHD incidences between the
exploratory and extended cohorts could be attributed to the
differences in the distribution of the stem-cell source, conditioning
Fig. 1 Association of DNA repair candidate genetic variants with aGvHD (grades2-4) in pediatric allo-HSCT. A Clinical association analysis
between DNA-repair SNP variants and aGvHD 2–4 in the exploratory cohort: forty-three SNPs were carried forward for statistical analysis.
Association analyses between genotype (additive or dominant models) against aGvHD 2–4 were tested using an X2 test (Fishers exact test, two
sided). Acute GVHD incidences in this cohort were 12%. In the x-axis, the gene and SNP identifications are given and in the y-axis their
significance for association with aGvHD 2–4 are shown as p values. B Clinical association analysis between MGMT rs10764881 and aGvHD 2–4
in the extended cohort. Cumulative incidence of acute Graft versus Host Disease (aGvHD 2–4) in the extended sample (N= 182) using
competing risk analysis and Cox-regression analysis to calculate the Hazard ratio (HR). Results plotted for MGMT rs10764881 genotype group
AA and AG versus GG. The number of patients with aGvHD 2–4 /total number of patients in each group is provided on the plot along with p
value and HR for this analysis. The numbers at risk for developing aGvHD 2–4 at each time interval on the x-axis is mentioned below the plot.
Table 3. Multivariable Cox Regression of aGvHD 2–4 (n= 182).















No serotherapy 1.08 1.01 1.15
Day 1 BU AUC 2.11 1.08 4.14 0.03
Variables included in the analysis (backward stepwise conditional cox-
regression analysis, removing variables with p > 0.2); GSTA1 (rapid and
normal metabolizer groups vs. slow metabolizer group); MGMT rs10764881
(GG vs. AA/AG); diagnosis (malignant vs. non-malignant); HLA matching
(MRD vs. MUD, MMRD, MMUD); stem-cell source (bone marrow vs.
peripheral blood stem cells vs. cord blood); chemotherapy (one alkylating
vs. two alkylating agents or three or with VP16); serotherapy (ATG vs. no
serotherapy); Day 1 BU AUC (mg × H/L)as a continuous variable harmo-
nized for the dosing schedule (1 × daily or 4 × daily).
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regimen used and aGvHD prophylaxis among the patients
between the cohorts. These differences could also be attributed
to center specific practices.
It is known that aGvHD grades 2–4 reduces the risk of relapse in
pediatric HSCT, especially in acute lymphoblastic leukemias
indicating significant graft versus leukemia effect in children in
aGvHD. Chronic GvHD was also shown to reduce the risk of relapse
mostly in acute myeloid leukemias (AML), with no survival
advantage in both scenarios [28]. We did not observe an association
of the MGMT rs10764881 with cumulative incidence of relapse. This
may possibly be explained by higher percentage of AML cases in
the cohort, varying disease status (heterogeneity) at the time of
HSCT and partly explained by the altered expression profiles of the
MGMT and its regulation by methylation status of its promoter in
cancer cells. In general, cancer tissues exhibit increased MGMT
activity compared to that of normal tissues [29], however,
concordance between MGMT activity and clinical outcomes in
HSCT setting remains to be determined. Several reports in pediatric
brain tumors have shown, that there is higher MGMT activity
compared to that seen in adults, responded poorly to the alkylating
agent temozolamide, and silencing MGMT in such tumors resulted
in better response [20] MGMT activity is also determined by
hypermethylation of its promoter that results in lower expression of
MGMT [30]. We could not investigate the methylation status of the
MGMT promoter in this study as varying exposures to various
chemotherapy drugs prior to the HSCT in children might have had
an impact on the methylation status of the MGMT promoter, that
may be more apparent in malignant cells (modulating the clinical
outcomes such as relapse) than in the normal cells. The relevance of
this genetic variant association in relation to the promoter
methylation needs to be investigated in future.
To conclude, children receiving BU-based myeloablative con-
ditioning prior to allo-HSCT and carrying MGMT rs10764881
variant are at increased risk of developing aGvHD 2–4. We
hypothesize that children with efficient MGMT function are at
lower risk of aaGvHD2–4 possibly by reducing the activation of
Phase 1 of the aGvHD cascade. MGMT rs10764881 should be
validated in an independent cohort, as a predictive marker of
aGvHD, in combination with other associated cytokine poly-
morphisms and non-genetic factors of the host to perform a pre-
transplant acute aGvHD risk assessment.
METHODS
Patient sample
Exploratory cohort. Sixty children who underwent an allo-HSCT after
myeloablative conditioning with BU/CY from 2001 to 2010 at CHU Saint-
Justine, Montreal, Canada. This sample was used to genotype fifty-one
chosen SNPs within seventeen DNA-repair genes.
Extended cohort. The study was extended to n= 187 by including 122
children who had undergone allo-HSCT at five different centers
(Supplementary Table 3). They were genotyped for those SNPs that
showed a significant association within the exploratory sample after
accounting for multiple testing correction (see Table 1 for the patient’s
characteristics). The Institutional Review Board at each center approved
the study and all patients and/or parents provided informed consent.
Details of inclusion criteria are available at Clinicaltrials.gov site
(NCT01257854) and the Australian New Zealand Clinical Trials registry
(ACTRN12612000544875).
Treatment: intravenous. BU (Busulfex®, Otsuka Pharmaceuticals, Saint-
Laurent, Montreal, QC, Canada or Busilvex®, Pierre Fabre Laboratory, Paris,
France) administration was given as a 2 h or 3 h infusion depending on
whether the patients were given four times daily or once daily dose,
respectively. BU first dose was either age or weight-based and
pharmacokinetic (PK) guided dose adjustment was performed in order
to obtain a cumulative AUC of 57.6–86.4 mg*h/L (Supplementary Table 1).
Co-medication to BU, aGvHD prophylaxis and serotherapy are summarized
in Table 1. All patients received non-manipulated grafts.
Clinical outcomes: aGvHD was graded according to established
grading criteria [31] and considered up to day 180 post HSCT [32].
Fig. 2 Reporter-gene assay on primary keratinocyte cells treated with and without dexamethasone. Site-specific mutations for MGMT were
designed dependent on the SNP of interest in the promoter region. Two fragments of 785 bp (short constructs), both excluding variant
rs10764881, but including another SNP, known as rs1625649 which is in high LD with rs10764881 (D′= 0.99 and R2= 0.84) were designed. The
two other fragments are longer, 1873bp, one that includes rs10764881 allele G and the other with rs10764881 allele A. All four fragments were
cloned into pGl4.10 in front of the firefly luciferase gene. Human epidermal primary keratinocytes (HEK cells) were co-transfected with each of
the pGL4.10 MGMT constructs and the pRL-SV40 vector that codes for Renilla luciferase for transfection control and normalization. Promoter-
less pGL4.10 plasmid was used to determine baseline expression. Measurement of Luciferase and Renilla activity was determined by Dual
luciferase assays. With the use of the MatInspector tool, a Glucocorticoid responsive element (GRE) was located near to variant rs10764881
and other areas within the plasmid construct region. Thus, to understand whether the enhancing effects are related to corticosteroids, HEK
cells transfected with the gene reporter plasmids were stimulated with 0.1 µM dexamethasone (Sigma, D8893) for 15 h and Luciferase
expression examined as previously and compared to the non-treated. Difference in promoter activity between the plasmid constructs was
assessed by t-test.
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Genotyping: Peripheral blood was collected prior to myeloablation and
the DNA extracted using a DNA extraction kit (FlexiGene DNA kit, Qiagen
GmbH, Hilden). Seventeen genes in total were chosen for investigation
(Table 2). We selected 17 candidate genes through a literature search from
key protein-coding genes in simple demethylating repair pathways (MGMT,
ALKBH1), BER pathway genes such as APEX1, LIG1, LIG4, and XRCC1 or
double-strand break repair pathways mainly associated with DNA cross-
linking by bifunctional alkylating agents such as BU (ATM, BRCA1, EXO1,
FAN1, FANCD2, MRE11, NBN, RAD50, RAD51, RFC1). See Supplementary
Material Methods for details on variant selection criteria.
Statistics analysis: All statistical analyses were performed using SPSS
software version 25 (IBM Corp) and R statistical software version 3.6.2.
Association analysis was performed with individual polymorphisms that
were in HWE and compared to the HapMap Caucasian population
MAF data.
Univariate analysis: The SNPs were tested for association with aGVHD
2–4 in the exploratory cohort; using a X2 test in a model (additive or
dominant) that best fit the data according to genotype frequency among
cases and controls. SNPs with a p value below a 0.001 cut off were retained
for further analysis according to the Bonferroni correction. Incidence of
aGvHD 2–4 was estimated using cumulative incidence function within
competing risk package (cmprsk) using R with death occurring before
aGvHD as a competing risk and compared using Grays’ test [33] for
significant associations. Clinical characteristics tested in the univariate
analysis in the extended cohort were HLA compatibility (matched related
donor vs. other donors); stem-cell source (bone marrow; peripheral blood
stem cells; cord blood); conditioning regimen (based on the number of
alkylating agents, one versus 2 or more,); underlying disease (malignant;
non-malignant); GSTA1 metabolic capacity based on diplotypes (classified
as slow vs. rapid and normal metabolizers);); serotherapy (not received
versus received). aGvHD prophylaxis was not assessed separately in the
statistical model as it was highly associated with the stem-cell source.
Variables with p value <0.1 were retained for multivariable analysis. Clinical
characteristics between the exploratory and extended cohorts were
compared using X2 test (categorical) or Mann–Whitney U test (continuous
variables).
Multivariable analysis: Significant SNPs were subsequently re-analysed
by competing risk analysis to compare the cumulative incidence of aGvHD
2–4. If still significant, they were retained for estimating the Hazard Ratios
with a 95% confidence interval (CI) in Cox-regression multivariable
analyses with additional risk factors (using a backward stepwise condi-
tional method). Risk factors in the multivariable analysis included: HLA
compatibility, stem-cell source; conditioning regimen, use of serotherapy;
baseline disease; GSTA1 metabolic capacity based on diplotypes [9]. Two
additional PK measures were included as continuous variables: first day BU
AUC and cumulative BU AUC. Both have previously been reported in
relation to toxicity [5, 9]. Additionally, the latter was included in order to
control for the variation in the target AUC across the conditioning
regimens. Multinomial logistic regression was used to assess the role of the
associated SNPs on aGvHD severity, by considering aGvHD grade 1 as
reference. For cellular assays, inhibitory concentration 50 (IC50) was
determined by nonlinear curve fitting of percent cell survival against
concentrations of BU for each cell line in GraphPad Prism, version 7.02.
Investigations examining the functional role of the associated
gene and variant(s)
MGMT mRNA expression pre and post Busulfan exposure. 22 CEPH
lymphoblastoid cell lines (Coriell Institute, New Jersey, USA) were obtained
with known genotypes extracted from the 1000 genome project (https://
www.ncbi.nlm.nih.gov/variation/tools/1000genomes) and used for mRNA
expression differences pre and post BU exposure (see Supplementary
Material Methods for details).
Cell viability studies on HAP1 MGMT knockouts. To understand the cellular
sensitivity of a cell when MGMT is knocked out and after exposure to BU, the
near-haploid human cell line HAP1 (Horizon discovery, Cambridge, UK) was
used. One Human HAP1 parental control cell line (C631) and one human
MGMT knock out, edited by CRISPR/Cas9 to contain a 20 bp deletion in a
coding exon of MGMT (HZGHC000430c006). These cell lines were treated (at
passage 2–4) with BU concentrations (25, 50, 100, 250, and 500 µM) for 48 h.
Experiments were performed in triplicate on three occasions. Real-Time Cell
growth inhibition was evaluated using the CellTiter 2.0 assay (Promega
Corporation, 2800 Woods Hollow Road, Madison, USA).
Dual luciferase reporter-gene assays
Functionality of the rs10764881 or for other SNPs that are in LD with this
SNP were assessed by site-specific mutations in MGMT promoter pGL4.10
luciferase reporter plasmid constructs (1.8 kb). Luciferase reporter activity
was measured by transfecting primary keratinocytes (see Supplementary
Material Methods).
Electrophoretic mobility shift assay (EMSA). EMSA was performed to test
the MGMT promoter DNA-protein binding (transcription factor) capacity of
the selected region and if it is influenced by the presence or absence of
variant (see Supplementary Material Methods for details).
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